Conference on 9th Annual Pricing and Reimbursement
|Event Date/Time: Sep 27, 2010||End Date/Time: Sep 29, 2010|
Delivering practical solutions and initiating winning strategies to streamline your P&R decisions
27th - 29th September 2010, BSG Conference Centre, London, UK
Dr. Jorge Mestre-Ferrandiz, Senior Economist, Office of Health Economics,
Andrea Rappagliosi, Vice President European Government Affairs & Head of Brussels Office, Glaxosmithkline,
Anne-Toni Rodgers, Senior Director, Government Affairs and Public Policy â€“ Europe Middle East and Africa, Baxter World Trade,
Janice Haigh, Senior Director, Pricing and Market Access â€“ Europe, Astellas Pharma,
Sarah Pitluck, Director, Global Government Affairs, Alexion Pharmaceuticals,
Luis Gonzalez Vaque, Member, British Institute of International and Comparative Law (BIICL),
Trevor Leighton, VP Pricing & Reimbursement, Shire,
Dr. Razmic Gregorian, Director, Simon-Kucher & Partner,
Prof. Mondher Toumi, Professor Market Access, University of Lyon,
Donald Macarthur, independent consultant & Principal, Justpharmareports,
Dr. Brian Smith, Editor, Journal of Medical Marketing, Pragmedic,
Dermot Glynn, Chairman, Europe Economics,
Adam Barak, Head of International Pricing and Reimbursement, United BioSource Corporation,
Nicole Mather, Consulting, Deloitte.
Reasons to register today:
â€¢ Discover the best methodologies to sustain effect of global recession
â€¢ Examine how to price to gain incremental patients in the emerging markets
â€¢ Assess the latest developments in HTA policy
â€¢ Analyse the impact of the healthcare reform bill in the US
â€¢ Learn how to develop an effective risk management plan
â€¢ Gain an insight of your productâ€™s potential price profile and optimise future returns
â€¢ Be part of the unparalleled networking
Who should attend?
VPs, Directors, Heads and Managers of:
â€¢ Pricing and Reimbursement
â€¢ Reimbursement & Market Access
â€¢ Strategic Pricing
â€¢ Price Monitoring
â€¢ Health Economics
â€¢ Commercial Pricing
â€¢ Economics and Government Affairs
â€¢ International Trade and Market Policy
â€¢ Parallel Trade
â€¢ Research and Development
â€¢ Business Strategy
â€¢ Sales & Marketing
â€¢ Brand Management
â€¢ Corporate Strategy
â€¢ Regulatory Affairs
â€¢ Public Affairs
â€¢ Outcomes Research
Others: Health Policy Advisors, Academics, Solution providers & consultants, Patient Representatives.
Pre-Conference Interactive Workshop
Monday 27th September, 2010,
Bottom of the Pyramid: How to price to gain incremental patients in the emerging markets
About the workshop:
â€¢ In which emerging markets does pricing by ability to pay matter the most?
â€¢ How should MNCs customise their portfolios in the emerging markets to maximise access by customer segment?
â€¢ What is the role of reference pricing in emerging markets and is there a creeping discipline for this outside Europe?
â€¢ How should branded generics be priced relative to other generic manufacturer competitors in the emerging markets?
â€¢ What type of relationship exists between price and volume in the emerging markets?
â€¢ Markets of consideration include, but are not limited to China, India, Brazil, Russia, Mexico, Turkey, and Poland
Presentation: HTAâ€™s New Frontier: Asiaâ€™s Emerging Evidence Networks
â€¢ What is the progress of HTA adoption in key emerging markets (Korea, Taiwan, Thailand, China, India)?
â€¢ How can we predict the timing of HTA adoption, implementation, and reliance using macroeconomic indicators?
â€¢ Where will these new agencies source their analyses manufacturers, domestic academic institutions, or international HTA agencies?
â€¢ Which therapeutic areas are at greatest risk, and in which markets?
About your workshop leader:
Cyrus Chowdhury is Vice President and leader of the global market access practice with Insight Strategy Advisors, possessing years of biopharmaceutical management consulting experience in the emerging and developed markets. His areas of expertise are global pricing, market access and portfolio optimisation. He has deep therapeutic area knowledge in CNS, oncology and inflammation, though his experience canvases many other high growth areas within the clinical realm. Mr. Chowdhury has managed and executed pricing and market access projects around the world, including within both developed and emerging economies. He possesses experience and a working knowledge of pharmaceutical pricing and market access policies in the US, Japan, UK, Germany, France, Spain, Italy, Canada markets. Additionally, he spent time in Asia managing pricing and market access projects in China, India, Korea and Australia. Today, his network spans throughout Central and Eastern Europe, Asia-Pacific, the Middle East, Latin America and Africa. Prior to joining ISA, Mr. Chowdhury was a Consultant with Cambridge Pharma Consultancy (now IMS), where he acquired extensive training and experience through years of project work. Additionally, Mr. Chowdhury served as a special independent consultant to Genzyme. In this capacity, he developed a comprehensive global parallel trade defense strategy and market entry sequencing for Genzyme while in Oxford. Mr. Chowdhury also spent two years with Fidelity Investments, specifically focusing on emerging biopharmaceutical and specialty pharmaceutical companies in CNS and Womenâ€™s Health. In addition to his commercial experiences, Mr. Chowdhury also performed clinical research with the UCLA School of Medicine in the Department of Urology. He published on such topics as pelvic floor disorders and bio-identical hormone replacement therapy. Mr. Chowdhury earned a Master in International Health Policy & Economics, with High Distinction from the London School of Economics, and a Bachelor of Arts in Neuroscience from Boston University, summa cum laude. He is frequently invited to speak in the EU, Asia and US on topics including emerging markets and global market access strategy.